Table 2.
Five independent SNPs associated with survival of NSCLC patients in the PLCO Trial GWAS dataset
| Variables | Category | Frequency | HR (95% CI) a | P a | HR (95% CI) b | P b |
|---|---|---|---|---|---|---|
| Age | Continuous | 1185 | 1.03 (1.02–1.05) | <0.0001 | 1.04 (1.02–1.05) | <0.0001 |
| Sex | Male/Female | 698/487 | 0.76 (0.65–0.88) | 0.0004 | 0.74 (0.63–0.87) | 0.0002 |
| Smoking status | Never/Current | 115/423 | 1.73 (1.29–2.33) | 0.0002 | 2.03 (1.5–2.74) | <0.0001 |
| Never/Former | 115/647 | 1.79 (1.36–2.36) | <0.0001 | 2.01 (1.51–2.68) | <0.0001 | |
| Histology | Adeno/Squam | 577/285 | 1.26 (1.04–1.51) | 0.0173 | 1.25 (1.03–1.52) | 0.0223 |
| Adeno/others | 577/323 | 1.38 (1.16–1.64) | 0.0003 | 1.40 (1.17–1.68) | 0.0002 | |
| Tumor stage | I-III/IV | 655/528 | 3.22 (2.65–3.91) | <0.0001 | 3.29 (2.70–4.02) | <0.0001 |
| Chemotherapy | No/Yes | 639/538 | 0.54 (0.45–0.65) | <0.0001 | 0.55 (0.46–0.66) | <0.0001 |
| Radiotherapy | No/Yes | 762/415 | 1.03 (0.87–1.21) | 0.7578 | 0.99 (0.84–1.17) | 0.9012 |
| Surgery | No/Yes | 637/540 | 0.21 (0.17–0.28) | <0.0001 | 0.19 (0.15–0.25) | <0.0001 |
| APOB, rs1801701_T, C>T | CC/CT/TT | 982/192/11 | 0.75 (0.62–0.90) | 0.0024 | 0.79 (0.66–0.96) | 0.0155 |
| CDH13, rs35859010_T, C>T | CC/CT/TT | 856/297/32 | 0.85 (0.74–0.99) | 0.0299 | 0.83 (0.71–0.96) | 0.0108 |
| CDH13, rs1833970_A, T>A | TT/TA/AA | 488/531/166 | 0.83 (0.75–0.93) | 0.0011 | 0.83 (0.74–0.92) | 0.0008 |
| CDH13, rs254315_C, T>C | TT/TC/CC | 863/300/22 | 1.24 (1.08–1.42) | 0.0023 | 1.33 (1.15–1.53) | <0.0001 |
| CDH13, rs425904_C, T>C | TT/TC/CC | 757/371/57 | 1.23 (1.08–1.39) | 0.0012 | 1.24 (1.09–1.40) | 0.0007 |
Abbreviations: SNP: single nucleotide polymorphisms; NSCLC, non-small cell lung cancer; GWAS, genome-wide association study; PLCO, Prostate, Lung, Colorectal and Ovarian cancer screening trial; HR: hazards ratio; CI: confidence interval.
Stepwise analysis included age, sex, smoking status, tumor stage, histology, chemotherapy, radiotherapy, surgery, PC1, PC2, PC3, PC4.
Fifteen published SNPs were used for post-stepwise adjustment: five SNPs were reported in previous publication (PMID: 27557513); One SNP was reported in the previous publication (PMID: 29978465); Two SNPs were reported in the previous publication (PMID: 30259978); Two SNPs were reported in the previous publication (PMID: 26757251); Three SNPs were reported in the previous publication (PMID: 30650190); Two SNPs were reported in the previous publication (PMID: 30989732); as well as adjusted by two significant SNPs have not published but been researching simultaneously in other pathway (related cell membrane transporters and trans-sulfation).